CD47 and myelodysplastic syndrome: In the field of oncology, CD47 was first identified as a tumor antigen in human ovarian cancer and has since been found to be overexpressed in several malignancies, including non-Hodgkin’s lymphoma, T-cell lymphoma, AML and myelodysplastic syndrome (MDS).